Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Diaz-Padilla

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Critical Reviews in Oncology/Hematology|April 9, 2013
Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysisIvan Diaz-Padilla, Nuria Romero, Eitan Amir, et al.
Gynecologic Oncology|May 5, 2012
Ovarian low-grade serous carcinoma: a comprehensive updateIvan Diaz-Padilla, Anais L Malpica, Lucas Minig, et al.
Ecancermedicalscience|January 4, 2014
Borderline tumours of the ovary, current controversies regarding their diagnosis and treatmentMaría Guadalupe Patrono, Lucas Minig, Ivan Diaz-Padilla, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
Journal of the National Cancer Institute|November 26, 2013
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysisFrancisco E Vera-Badillo, Arnoud J Templeton, Paulo de Gouveia, et al.
Investigational New Drugs|February 12, 2022
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumorsSaiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
JTO Clinical and Research Reports|October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLCSun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Critical Reviews in Oncology/Hematology|April 9, 2013
Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysisIvan Diaz-Padilla, Nuria Romero, Eitan Amir, et al.
Gynecologic Oncology|May 5, 2012
Ovarian low-grade serous carcinoma: a comprehensive updateIvan Diaz-Padilla, Anais L Malpica, Lucas Minig, et al.
Ecancermedicalscience|January 4, 2014
Borderline tumours of the ovary, current controversies regarding their diagnosis and treatmentMaría Guadalupe Patrono, Lucas Minig, Ivan Diaz-Padilla, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
Journal of the National Cancer Institute|November 26, 2013
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysisFrancisco E Vera-Badillo, Arnoud J Templeton, Paulo de Gouveia, et al.
Investigational New Drugs|February 12, 2022
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumorsSaiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
JTO Clinical and Research Reports|October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLCSun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Pageof 4